-
Innovative RNAi therapeutics for autoimmune, cardiovascular, obesity and metabolic diseases
SanegeneBio is developing a globally integrated drug discovery and development engine, achieving best-in-class and first-in-class potential with LEAD™ technology.
Pioneering Transformative RNAi Therapeutics for Chronic Diseases
We're advancing a pipeline of best-in-class and first-in-class RNAi therapeutics targeting autoimmune, cardiovascular, obesity and metabolic diseases, and beyond.
Ligand and Enhancer Assisted Delivery (LEAD™) Technology
Our LEAD™ platform utilizes novel receptor-mediated internalization mechanisms and tailored enhancers to achieve targeted delivery to extrahepatic tissues and cells of therapeutic relevance.
What Makes Us Different
Targeted to adipocytes, skeletal myocytes, cardiomyocytes, and other therapeutically relevant cell types
Receptor-mediated delivery enabled by ligand and enhancer design, with tunable pharmaceutical properties
Bi-annual subcutaneous dosing potential with exquisite safety profile
SanegeneBio pioneers RNAi medicines with optimized payloads and proprietary delivery technologies for both liver and extra-hepatic targets to expand therapeutic potential.
-
Clinical stage, fully integrated and global biotechnology company, laser focused on unlocking the full potential of RNAi therapeutics
-
A pipeline of best-in-class and first-in-class RNAi therapeutics focused on autoimmune, cardiovascular, obesity and metabolic diseases
-
Proprietary, differentiated delivery technologies enabling safe, selective and durable mRNA silencing in tissues of therapeutic relevance